GEARBOx - a multisite clinical trial matching tool for children with relapsed or refractory cancer

GEARBOx - 针对复发或难治性癌症儿童的多中心临床试验匹配工具

• 批准号: 10707901
• 负责人: Samuel Volchenboum
• 金额: $ 52.65万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-21 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10707901
• 关键词: 3-Dimensional; Acceleration; Acute Lymphocytic Leukemia; Acute Myelocytic Leukemia; Agreement; Algorithms; Biological Markers; Cancer Relapse; Characteristics; Chicago; Child; Childhood Acute Myeloid Leukemia; Clinical; Clinical Data; Clinical Trials; Collaborations; Community Healthcare; Complex; Data; Data Commons; Data Sources; Development; Disease; Eligibility Determination; Enrollment; Ewings sarcoma; Exclusion Criteria; Feedback; Flow Cytometry; Genomics; Hematology; Immunophenotyping; Improve Access; International; Logic; Malignant Childhood Neoplasm; Malignant Neoplasms; Manuals; Measures; Methods; Monitor; Multi-Institutional Clinical Trial; Multiomic Data; Natural Language Processing; Neuroblastoma; Outcome; Patients; Pediatric Oncologist; Pediatric Oncology; Pharmaceutical Preparations; Pharmacologic Substance; Precision therapeutics; Process; Protocols documentation; Rare Diseases; Recurrent disease; Refractory; Refractory Disease; Relapse; Research Personnel; Resources; Rhabdomyosarcoma; Site; Societies; Solid Neoplasm; Source; Specific qualifier value; Structure; System; Testing; Time; Universities; Visualization; Work; chemotherapy; cooperative study; data sharing; improved; improved outcome; leukemia/lymphoma; novel therapeutics; osteosarcoma; participant enrollment; precision medicine; refractory cancer; success; targeted therapy trials; tool; tumor; unsupervised learning; usability

PROJECT SUMMARY / ABSTRACT Despite a steady rise in cure rates, cancer remains deadly for many children, especially those with relapsed or refractory disease. Precision medicine holds great promise for these kids, but matching children to available clinical trials remains a challenge due a lack of up-to-date information and highly complex eligibility criteria based on clinical information and genomic and immunophenotype biomarker data. In collaboration with The Leukemia & Lymphoma Society, the Pediatric Cancer Data Commons (PCDC) team has developed GEARBOx (Genomic Eligibility Algorithm at Relapse for Better Outcomes), a clinical trial matching tool to allow clinicians to quickly find potential matches for their patients with relapsed or refractory acute myelogenous leukemia (AML). We now endeavor to expand GEARBOx to include several more tumor types, including acute lymphoblastic leukemia, neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, and osteosarcoma. Additionally, we will augment the often-manual abstraction of eligibility criteria from clinical trials with new automated methods. The information available to clinicians about trials will be supplemented to include critical data for how to quickly and efficiently enroll a child on a matched study. Finally, the PCDC team will partner with a third-party flow cytometry lab (Hematologics) to create ways to automatically pull and incorporate structured immunophenotype data directly into the GEARBOx tool. These enhancements will greatly enhance the process of finding appropriate clinical trials for patients and then getting them enrolled, thus improving access to critical precision therapy for these children.

项目摘要 /摘要 尽管治愈率稳步上升，但对于许多儿童来说，癌症仍然是致命的，尤其是患有复发或的儿童 难治性疾病。精密药物对这些孩子有很大的希望，但使孩子与可用的孩子相匹配 由于缺乏最新信息和高度复杂的资格标准，临床试验仍然是一个挑战 基于临床信息以及基因组和免疫表型生物标志物数据。与 小儿癌症数据共享（PCDC）团队的白血病和淋巴瘤协会已经开发了变速箱 （基因组资格算法复发以获得更好的结果），这是一种临床试验匹配工具，允许临床医生 快速找到患有复发或难治性急性髓性白血病的患者的潜在匹配 （AML）。现在，我们努力扩展变速箱，包括更多的肿瘤类型，包括急性 淋巴细胞白血病，神经母细胞瘤，横纹肌肉瘤，尤因肉瘤和骨肉瘤。此外， 我们将增加具有新自动化的临床试验中的资格标准的经常手动抽象 方法。临床医生可用的有关试验的信息将得到补充，以包括关键数据 如何快速有效地让孩子参加匹配的研究。最后，PCDC团队将与 第三方流式细胞仪实验室（血液学）创建自动拉动和合并结构化的方法 免疫表型数据直接进入变速箱工具。这些增强能力将大大增强过程 为患者寻找适当的临床试验，然后让他们入学，从而改善获得关键的机会 这些孩子的精确疗法。